Evidence map›Paper›PMID 26628876›Full record

ArticleCurrent oncology (Toronto, Ont.)2015

Human albumin eye drops as a therapeutic option for the management of keratoconjunctivitis sicca secondary to chronic graft-versus-host disease after stem-cell allografting.

J T Seki, N Sakurai, S Moldenhauer, J Dam, E G Atenafu, P M Yip, T Mazzulli, T Henderson, J Pendergrast, C Cserti and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. [Ocular graft versus host disease : Corneal complications].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2017
    Review
  5. TFOS DEWS II Tear Film Report.The ocular surface · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

J T SekiPrincess Margaret Cancer Centre, Toronto, ON; ; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON; ; College of Pharmacy and Health Sciences, Drake University, IA, U.S.A.;
N SakuraiPrincess Margaret Cancer Centre, Toronto, ON;
S MoldenhauerPrincess Margaret Cancer Centre, Toronto, ON; ; College of Pharmacy and Health Sciences, Drake University, IA, U.S.A.;
J DamPrincess Margaret Cancer Centre, Toronto, ON;
E G AtenafuPrincess Margaret Cancer Centre, Toronto, ON;
P M YipToronto General Hospital, Toronto, ON;
T MazzulliLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON; ; Mount Sinai Hospital, Toronto, ON;
T HendersonThe Hospital for Sick Children, Toronto, ON.
J PendergrastToronto General Hospital, Toronto, ON;
C CsertiToronto General Hospital, Toronto, ON;
J P VelazquezPrincess Margaret Cancer Centre, Toronto, ON;
R SimpsonPrincess Margaret Cancer Centre, Toronto, ON;
G FellugaPrincess Margaret Cancer Centre, Toronto, ON;
H A MessnerPrincess Margaret Cancer Centre, Toronto, ON;
J H LiptonPrincess Margaret Cancer Centre, Toronto, ON;
Princess Margaret Cancer Centre · CAMount Sinai Hospital · CAHospital for Sick Children · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKeratoconjunctivitis sicca from chronic graft-versus-host disease (cgvhd) after allogeneic stem cell transplantation is common, leading to severe corneal damage and blindness if not treated. We retrospectively examined the efficacy and safety of pooled human albumin eye drops (haeds) for symptom relief in 40 stem-cell transplantation patients after other alternatives had failed.

methodsThe Common Terminology Criteria for Adverse Events (version 4.0) and the cgvhd grading scale were used to compare response in the patients during January 2000 and July 2013. In addition, on days 1 and 30, the haeds were subjected to quality assurance testing for sterility, oncotic pressure, albumin measurement, viscosity, pH, and purity by protein electrophoresis.

resultsUse of haeds resulted in symptom relief for 37 patients (92.5%); 3 patients (7.5%) failed to improve with use of haeds (p ≤ 0.0001). Of the 37 patients having symptom relief, 7 (19%) improved from grade 3 to no dry eye symptoms. Proportionately, post-treatment symptom improvement by two grade levels, from 3 to 1 (70%), was significantly higher than improvement by one grade level, from 3 to 2 (11%) or from 2 to 1 (19%, p ≤ 0.0001). Time to symptom relief ranged from 2 weeks to 28 weeks. Of the 40 patients, 38 (95%) had no adverse reactions. Days 1 and 30 quality assurance testing results were equivalent.

conclusionsComplications of keratoconjunctivitis sicca were well managed and well tolerated with haeds when other remedies failed. Quality assurance testing confirmed that haeds were safe and stable in extreme conditions.

Indexed as

Post-transplant dry eye management

Identifiers

PMID26628876
PMCPMC4608409
OpenAlexW1778499310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.